Clinical pharmacokinetics of tacrolimus in heart transplant recipients

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 2-7

  Regazzi, Mario B ^a   Rinaldi, Mauro ^b   Molinaro, Mariadelfina ^b   Pellegrini, Carlo ^b   Calvi, Monica ^b   Arbustini, Eloisa ^b   Bellotti, Elena ^b   Bascapè, Vanni ^b   Martinelli, Luigi ^b   Viganò, Mario ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

Heart transplantation; Pharmacokinetics; Tacrolimus

Indexed keywords

AZATHIOPRINE; CEFAZOLIN; METHYLPREDNISOLONE; NYSTATIN; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TACROLIMUS;

EID: 0033024907     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00002     Document Type: Article

References (29)

1. Goto T, Kino T, Hatanaka H, et al. FK506: historical perspectives. Transplant Proc 1991;23:2713-7.
2. Tanaka H, Kuroda A, Marusawa H, et al.Physicochemical properties of FK506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19(suppl 6):11-6.
3. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
4. Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:1000-4.
5. Roberts JP, Lake JR, Hebert M, Nikolai B, Ascher NL, Ferrell LD. Reversal of chronic rejection after treatment failure with FK506 and RS61443. Transplantation 1993;56:1021-3.
6. Kelly PA, Burkart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995;52: 1521-35.
7. MacDonald AS, Sketris IS. Tacrolimus in transplantation. Am J Health Syst Pharm 1995;52(14):1596-71.
8. Sattler M, Guengerich FP, Yun C, Christians U, Sewing K, Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
9. Schwartz M, Holst B, Facklam D, Buell D. FK506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US multicenter FK506 dose optimization. Transplant Proc 1995;27:1107.
10. Shaw LM, Brayman KL. FK506 therapeutic drug monitoring. Clin Chem 1994;40:2207-8.
11. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
12. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506/prednisone vs FK506/azathioprine/prednisone in renal transplant patients. Transplant Proc 1995;27: 814-7.
13. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991;23:3054-7.
14. Rinaldi M, Pellegrini C, Martinelli L, et al. FK506 Effectiveness in reducing acute rejection after heart transplantation: A prospective randomized study. J Heart Lung Transplant 1997;16:1001-10.
15. Kreter B, Woods M, Antibiotic prophylaxixs for cardiothoracic operations. J Thorac Cardiovasc Surg 1992; 104: 590-9.
16. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for the IMx® analyzer. Transplant Proc 1991, 23:2748-9.
17. Simed. Pharm-NCA, non-compartmental pharmacokinetic data analysis software. Créteil, France: Simed.
18. Simed. PPHARM, a population pharmacokinetic-dynamic data modeling program. Créteil, France: Simed.
19. Pham SM, Kormos RL, Kawai A, et al. FK506 in clinical cardiac transplantation: A five-year experience. Proceedings of international congress on new immunosuppressive drugs. Minneapolis, Minnesota, U.S.A., August 27-30. 1995:94.
20. Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit M, Pichlmayr R. Association of elevated FK506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991;23: 3153-5.
21. Fung JJ, Starzl TE. FK506 in solid organ transplantation. Transplant Proc 1994;26:3017-20.
22. Gonschior A-K, Christians U, Braun F, et al. Measurements of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by HPLC-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol 1994;38:567-71.
23. Japanese FK506 Study Group. Japanese Study of FK506 on kidney transplantation: the benefit of monitoring the whole blood FK506 concentration. Transplant Proc 1991;23:3085-8.
24. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-90.
25. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6
26. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994;57:519-25.
27. The U.S. Multicenter FK506 Liver Study Group. A comparision of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation: correlation of whole blood levels and efficacy and toxicity. N Engl J Med 1994;331:1110-5
28. McMaster P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995;17:602-5.
29. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995;17:606-14.